- Home
- SCYX vs BLUE Comparison
SCYX vs BLUE Comparison
Compare SCYX & BLUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCYX
- BLUE
- Stock Information
- Founded
- SCYX 1999
- BLUE 1992
- Country
- SCYX United States
- BLUE United States
- Employees
- SCYX N/A
- BLUE N/A
- Industry
- SCYX Biotechnology: Pharmaceutical Preparations
- BLUE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SCYX Health Care
- BLUE Health Care
- Exchange
- SCYX Nasdaq
- BLUE Nasdaq
- Market Cap
- SCYX 36.8M
- BLUE 36.9M
- IPO Year
- SCYX 2014
- BLUE 2013
- Fundamental
- Price
- SCYX $0.88
- BLUE $4.97
- Analyst Decision
- SCYX
- BLUE Hold
- Analyst Count
- SCYX 0
- BLUE 7
- Target Price
- SCYX N/A
- BLUE $44.60
- AVG Volume (30 Days)
- SCYX 204.8K
- BLUE 1.1M
- Earning Date
- SCYX 05-15-2025
- BLUE 05-14-2025
- Dividend Yield
- SCYX N/A
- BLUE N/A
- EPS Growth
- SCYX N/A
- BLUE N/A
- EPS
- SCYX N/A
- BLUE N/A
- Revenue
- SCYX $2,630,000.00
- BLUE $103,946,000.00
- Revenue This Year
- SCYX $460.12
- BLUE $205.45
- Revenue Next Year
- SCYX $253.87
- BLUE $3.74
- P/E Ratio
- SCYX N/A
- BLUE N/A
- Revenue Growth
- SCYX N/A
- BLUE 127.51
- 52 Week Low
- SCYX $0.72
- BLUE $3.20
- 52 Week High
- SCYX $2.60
- BLUE $28.60
- Technical
- Relative Strength Index (RSI)
- SCYX 48.64
- BLUE 62.82
- Support Level
- SCYX $0.72
- BLUE $4.40
- Resistance Level
- SCYX $1.02
- BLUE $5.01
- Average True Range (ATR)
- SCYX 0.08
- BLUE 0.11
- MACD
- SCYX 0.00
- BLUE 0.06
- Stochastic Oscillator
- SCYX 51.70
- BLUE 96.72
About SCYX SCYNEXIS Inc.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
About BLUE bluebird bio Inc.
bluebird bio Inc is a biotechnology company engaged in researching, developing, and commercializing potentially curative gene therapies for severe genetic diseases based on its proprietary lentiviral vector (LVV) gene addition platform. The Company operates in a single segment, focusing on researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases.